HDRN Canada

Scientific Director and CEO’s Report

February 22, 2024

# High Level Progress Update

## Key progress since the last Board meeting:

* HDRN Canada and the IDEA Team completed Phase 2 of the IDEA Strategy Facilitation Process, including 10 focus groups with all Working Groups (WGs) and Teams, the Executive Committee, and the Board.
* The Canadian Drug Agency Transition Office (CDATO) awarded HDRN Canada $379K in funding to determine the benefits of conducting multi-regional studies using the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) at five sites (BC, AB, MB, ON, and CIHI), as compared with the existing practice.
* The Real World Evidence Service (RWES) initiative funded by CDATO and the Canadian Agency for Drugs and Technologies in Health (CADTH) is progressing well. The final agreements are completed for the two use cases to serve pan-Canadian health sector organizations. The Partnerships Portfolio also organized two major workshops for ethics professionals and HDRN Canada sites / knowledge users to explore key issues and models for the RWES emerging design.
* The Memorandum of Understanding between CIHI and HDRN Canada is now signed.

## Major milestones for the coming quarter:

* In the coming quarter the IDEA Team will be completing the IDEA Strategic Plan and associated Action Plan. The final report is expected by March/April 2024.
* The DASH Operating Model / Organizational Review is ongoing, with the final report extended to March 2024 to allow adequate time for consultations.

## Anticipated and ongoing challenges:

* There are risks with developing the IDEA Strategy including unachieved improvements and managing expectations. This will require ongoing attention and conversation.
* The RWES initiative also remains a significant change management process for HDRN Canada sites with sufficient time needed to develop this new service. This will require change champions, ongoing engagement, and continuous feedback mechanisms.